Table of Contents
Chemotherapy Research and Practice
Volume 2016 (2016), Article ID 3439707, 5 pages
http://dx.doi.org/10.1155/2016/3439707
Clinical Study

The Efficacy, Safety, and Cost Benefit of Olanzapine versus Aprepitant in Highly Emetogenic Chemotherapy: A Pilot Study from South India

1Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bangalore 560030, India
2Department of Community Health, St. John’s Medical College, Bangalore 560034, India

Received 29 September 2015; Revised 12 December 2015; Accepted 21 December 2015

Academic Editor: Kazuo Tamura

Copyright © 2016 Govind Babu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Laszlo, “Emesis as limiting toxicity in cancer chemotherapy,” in Antiemetics and Cancer Chemotherapy, J. Laszlo, Ed., pp. 1–5, Lippincott Williams & Wilkins, Baltimore, Md, USA, 1983. View at Google Scholar
  2. R. J. Ingle, T. G. Burish, and K. A. Wallston, “Conditionability of cancer chemotherapy patients,” Oncology Nursing Forum, vol. 11, no. 4, pp. 97–102, 1984. View at Google Scholar · View at Scopus
  3. E. P. Mitchell, “Gastrointestinal toxicity of chemotherapeutic agents,” Seminars in Oncology, vol. 19, no. 5, pp. 566–579, 1992. View at Google Scholar · View at Scopus
  4. J. L. Richardson, G. Marks, and A. Levine, “The influence of symptoms of disease and side effects of treatment on compliance with cancer therapy,” Journal of Clinical Oncology, vol. 6, no. 11, pp. 1746–1752, 1988. View at Google Scholar · View at Scopus
  5. M. G. Kris, R. J. Gralla, R. A. Clark et al., “Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin,” Journal of Clinical Oncology, vol. 3, no. 10, pp. 1379–1384, 1985. View at Google Scholar · View at Scopus
  6. F. Roila, E. Boschetti, M. Tonato et al., “Predictive factors of delayed emesis in cisplatin-treated patients and antiemetic activity and tolerability of metoclopramide or dexamethasone. A randomized single-blind study,” American Journal of Clinical Oncology, vol. 14, no. 3, pp. 238–242, 1991. View at Google Scholar · View at Scopus
  7. F. Roila, P. J. Hesketh, and J. Herrstedt, “Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference,” Annals of Oncology, vol. 17, no. 1, pp. 20–28, 2006. View at Publisher · View at Google Scholar
  8. D. Moher, A. Z. Arthur, and J. L. Pater, “Anticipatory nausea and/or vomiting,” Cancer Treatment Reviews, vol. 11, no. 3, pp. 257–264, 1984. View at Publisher · View at Google Scholar · View at Scopus
  9. P. B. Jacobsen and W. H. Redd, “The development and management of chemotherapy-related anticipatory nausea and vomiting,” Cancer Investigation, vol. 6, no. 3, pp. 329–336, 1988. View at Publisher · View at Google Scholar · View at Scopus
  10. F. Roila, J. Herrstedt, M. Aapro et al., “Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference,” Annals of Oncology, vol. 21, no. 5, pp. v232–v243, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. J. M. Koeller, M. S. Aapro, R. J. Gralla et al., “Antiemetic guidelines: creating a more practical treatment approach,” Supportive Care in Cancer, vol. 10, no. 7, pp. 519–522, 2002. View at Publisher · View at Google Scholar · View at Scopus
  12. M. G. Kris, P. J. Hesketh, M. R. Somerfield et al., “American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006,” Journal of Clinical Oncology, vol. 24, no. 18, pp. 2932–2947, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. P. J. Hesketh, S. M. Grunberg, R. J. Gralla et al., “The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin—the Aprepitant Protocol 052 Study Group,” Journal of Clinical Oncology, vol. 21, no. 22, pp. 4112–4119, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Herrstedt, “Antiemetics: an update and the MASCC guidelines applied in clinical practice,” Nature Clinical Practice Oncology, vol. 5, no. 1, pp. 32–43, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. P. J. Hesketh, M. G. Kris, S. M. Grunberg et al., “Proposal for classifying the acute emetogenicity of cancer chemotherapy,” Journal of Clinical Oncology, vol. 15, no. 1, pp. 103–109, 1997. View at Google Scholar · View at Scopus
  16. National Comprehensive Cancer Network, Antiemesis Version 2, 2015, http://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf.
  17. R. M. Navari, L. H. Einhorn, S. D. Passik et al., “A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study,” Supportive Care in Cancer, vol. 13, no. 7, pp. 529–534, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Srivastava, N. Brito-Dellan, M. P. Davis, M. Leach, and R. Lagman, “Olanzapine as an antiemetic in refractory nausea and vomiting in advanced cancer,” Journal of Pain and Symptom Management, vol. 25, no. 6, pp. 578–582, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. S. D. Passik, R. M. Navari, S.-H. Jung et al., “A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study,” Cancer Investigation, vol. 22, no. 3, pp. 383–388, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. S. D. Passik, K. L. Kirsh, D. E. Theobald et al., “A retrospective chart review of the use of olanzapine for the prevention of delayed emesis in cancer patients,” Journal of Pain and Symptom Management, vol. 25, no. 5, pp. 485–488, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. S. D. Passik, J. Lundberg, K. L. Kirsh et al., “A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain,” Journal of Pain and Symptom Management, vol. 23, no. 6, pp. 526–532, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. R. J. G. Arnold and S. Ekins, “Time for cooperation in health economics among the modelling community,” PharmacoEconomics, vol. 28, no. 8, pp. 609–613, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. N. Mizukami, M. Yamauchi, K. Koike et al., “Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study,” Journal of Pain and Symptom Management, vol. 47, no. 3, pp. 542–550, 2014. View at Publisher · View at Google Scholar · View at Scopus